---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032281"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:57:53.908627+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q3 net loss $14.3M; EsoGuard test volume up 436% YoY to 1,088

## Summary
- GAAP net loss attributable to common stockholders $14.3M (-$0.39/share); non-GAAP adjusted loss $10.2M (-$0.28/share).
- EsoGuard test volume 1,088 in Q3 (+28% sequential, +436% YoY); EsoGuard-related revenue $0.1M.
- Cash and equivalents $26.9M at Sep 30, 2022, down from $53.7M at Dec 31, 2021; committed equity facility up to $50M.
- Sales team at 37, target 58 early 2023. 13 Lucid Test Centers in 11 states; 3 more by year-end.
- EsoCheck production moved to Coastline International; expects 60% reduction in per-unit manufacturing cost.

## SEC filing metadata
- accession: 0001493152-22-032281
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/0001493152-22-032281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032281
- JSON: https://secwatch.observer/filing/0001493152-22-032281.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032281.txt

## Key facts
- Earnings Releases
  Lucid Diagnostics Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $14.3 million, EPS $(0.39) per common share.
  - Period: the three months ended September 30, 2022
  - Revenue: $0.1 million
  - Net income: approximately $14.3 million
  - EPS: $(0.39) per common share
  - Result: reported results
  source text: For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $14.4 million, including stock-based compensation expenses of $3.6 million. GAAP net loss attributable to common stockholders was approximately $14.3 million, or $(0.39) per common share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/0001493152-22-032281-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.